Advertisement
Archival Report|Articles in Press

Genome-wide Association Study points to novel locus for Gilles de la Tourette Syndrome

Published:February 02, 2023DOI:https://doi.org/10.1016/j.biopsych.2023.01.023

      Abstract

      Background

      Tourette Syndrome (TS) is a childhood-onset neurodevelopmental disorder of complex genetic architecture, characterized by multiple motor tics and at least one vocal tic persisting for more than one year.

      Methods

      We performed a genome-wide meta-analysis integrating a novel TS cohort with previously published data, resulting in a sample size of 6,133 TS individuals and 13,565 ancestry-matched controls.

      Results

      We identified a genome-wide significant locus on chromosome 5q15. Integration of eQTL, Hi-C and GWAS data implicated the NR2F1 gene and associated lncRNAs within the 5q15 locus. Heritability partitioning identified statistically significant enrichment in brain tissue histone marks, while polygenic risk scoring on brain volume data identified statistically significant associations with right and left thalamus volumes and right putamen volume.

      Conclusions

      Our work presents novel insights in the neurobiology of TS opening up new directions for future studies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Robertson MM, Cavanna AE, Eapen V (2015): Gilles de la Tourette syndrome and disruptive behavior disorders: prevalence, associations, and explanation of the relationships. J Neuropsychiatry Clin Neurosci 27: 33–41.

      2. Scharf JM, Miller LL, Gauvin CA, Alabiso J, Mathews CA, Ben-Shlomo Y (2015): Population prevalence of Tourette syndrome: A systematic review and meta-analysis. Movement Disorders, vol. 30. pp 221–228.

      3. Robertson MM, Eapen V, Cavanna AE (2009): The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 67: 475–483.

      4. Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. (2013): Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet 9: e1003864.

      5. Robertson MM, Eapen V, Singer HS, Martino D, Scharf JM, Paschou P, et al. (2017): Gilles de la Tourette syndrome. Nat Rev Dis Primers 3: 16097.

      6. Mataix-Cols D, Isomura K, Pérez-Vigil A, Chang Z, Rück C, Larsson KJ, et al. (2015): Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study. JAMA Psychiatry 72: 787–793.

      7. Yu D, Sul JH, Tsetsos F, Nawaz MS, Huang AY, Zelaya I, et al. (2019): Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. Am J Psychiatry 176: 217–227.

      8. Huang AY, Yu D, Davis LK, Sul JH, Tsetsos F, Ramensky V, et al. (2017): Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. Neuron 94: 1101–1111.e7.

      9. Wang S, Mandell JD, Kumar Y, Sun N, Morris MT, Arbelaez J, et al. (2018): De Novo Sequence and Copy Number Variants Are Strongly Associated with Tourette Disorder and Implicate Cell Polarity in Pathogenesis. Cell Rep 25: 3544.

      10. Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, et al. (2013): Genome-wide association study of Tourette’s syndrome. Mol Psychiatry 18: 721–728.

      11. Tsetsos F, Yu D, Sul JH, Huang AY, Illmann C, Osiecki L, et al. (2021): Synaptic processes and immune-related pathways implicated in Tourette syndrome. Transl Psychiatry 11: 56.

      12. Abdulkadir M, Mathews CA, Scharf JM, Yu D, Tischfield JA, Heiman GA, et al. (2019): Polygenic Risk Scores Derived From a Tourette Syndrome Genome-wide Association Study Predict Presence of Tics in the Avon Longitudinal Study of Parents and Children Cohort. Biological Psychiatry, vol. 85. pp 298–304.

      13. Yang Z, Wu H, Lee PH, Tsetsos F, Davis LK, Yu D, et al. (2021): Investigating Shared Genetic Basis Across Tourette Syndrome and Comorbid Neurodevelopmental Disorders Along the Impulsivity-Compulsivity Spectrum. Biol Psychiatry 90: 317–327.

      14. Schrag A, EMTICS Collaborative Group, Martino D, Apter A, Ball J, Bartolini E, et al. (2019): European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. European Child & Adolescent Psychiatry, vol. 28. pp 91–109.

      15. Forde NJ, Kanaan AS, Widomska J, Padmanabhuni SS, Nespoli E, Alexander J, et al. (2016): TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. Front Neurosci 10: 384.

      16. Karagiannidis I, Rizzo R, Tarnok Z, Wolanczyk T, Hebebrand J, Nöthen MM, et al. (2012): Replication of association between a SLITRK1 haplotype and Tourette Syndrome in a large sample of families. Mol Psychiatry 17: 665–668.

      17. Nöthlings U, Krawczak M (2012): PopGen: Eine populationsbasierte Biobank mit Langzeitverfolgung der Kontrollkohorte (Leitthema). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55: 831–835.

      18. 3C Study Group (2003): Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. Neuroepidemiology 22: 316–325.

      19. Das S, Forer L, Schönherr S, Sidore C, Locke AE, Kwong A, et al. (2016): Next-generation genotype imputation service and methods. Nat Genet 48: 1284–1287.

      20. Consortium THR, the Haplotype Reference Consortium (2016): A reference panel of 64,976 haplotypes for genotype imputation. Nature Genetics, vol. 48. pp 1279–1283.

      21. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006): Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904–909.

      22. Patterson N, Price AL, Reich D (2006): Population structure and eigenanalysis. PLoS Genet 2: e190.

      23. Bulik-Sullivan BK, Loh P-R, Finucane H, Ripke S, Yang J, Patterson N, et al. (n.d.): LD Score Regression Distinguishes Confounding from Polygenicity in Genome-Wide Association Studies. https://doi.org/10.1101/002931

      24. Perreault L-PL (2020): Pgxcentre/region-Plot: Release 0.1.4. https://doi.org/10.5281/zenodo.4095310

      25. Han B, Eskin E (2012): Interpreting meta-analyses of genome-wide association studies. PLoS Genet 8: e1002555.

      26. Han B, Eskin E (2011): Random-Effects Model Aimed at Discovering Associations in Meta-Analysis of Genome-wide Association Studies. The American Journal of Human Genetics, vol. 88. pp 586–598.

      27. Urbut SM, Wang G, Carbonetto P, Stephens M (n.d.): Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions. https://doi.org/10.1101/096552

      28. Finucane HK, ReproGen Consortium, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, et al. (2015): Partitioning heritability by functional annotation using genome-wide association summary statistics. Nature Genetics, vol. 47. pp 1228–1235.

      29. Roadmap Epigenomics Consortium, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. (2015): Integrative analysis of 111 reference human epigenomes. Nature 518: 317–330.

      30. Choi SW, O’Reilly PF (2019): PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience 8. https://doi.org/10.1093/gigascience/giz082

      31. Watanabe K, Taskesen E, van Bochoven A, Posthuma D (2017): Functional mapping and annotation of genetic associations with FUMA. Nat Commun 8: 1826.

      32. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. (2013): The Genotype-Tissue Expression (GTEx) project. Nat Genet 45: 580–585.

      33. GTEx Consortium (2020): The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369: 1318–1330.

      34. Wang Y, Song F, Zhang B, Zhang L, Xu J, Kuang D, et al. (2018): The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. Genome Biol 19: 151.

      35. Jung I, Schmitt A, Diao Y, Lee AJ, Liu T, Yang D, et al. (2019): A compendium of promoter-centered long-range chromatin interactions in the human genome. Nature Genetics, vol. 51. pp 1442–1449.

      36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. (2007): PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.

      37. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015): Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4: 7.

      38. de Leeuw C, Goudriaan A, Smit AB, Yu D, Mathews CA, Scharf JM, et al. (2015): Involvement of astrocyte metabolic coupling in Tourette syndrome pathogenesis. Eur J Hum Genet 23: 1519–1522.

      39. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. (2018): The UK Biobank resource with deep phenotyping and genomic data. Nature 562: 203–209.

      40. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW (2019): Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun 10: 1776.

      41. Millard LAC, Davies NM, Gaunt TR, Davey Smith G, Tilling K (2018): Software Application Profile: PHESANT: a tool for performing automated phenome scans in UK Biobank. Int J Epidemiol 47: 29–35.

      42. Satizabal CL, Adams HHH, Hibar DP, White CC, Knol MJ, Stein JL, et al. (2019): Genetic architecture of subcortical brain structures in 38,851 individuals. Nat Genet 51: 1624–1636.

      43. Euesden J, Lewis CM, O’Reilly PF (2015): PRSice: Polygenic Risk Score software. Bioinformatics 31: 1466–1468.

      44. Mufford M, Cheung J, Jahanshad N, van der Merwe C, Ding L, Groenewold N, et al. (n.d.): Concordance of Genetic Variation that Increases Risk for Tourette Syndrome and that Influences its Underlying Neurocircuitry. https://doi.org/10.1101/366294

      45. Goodart SA, Butler MG, Overhauser J (1996): Familial double pericentric inversion of chromosome 5 with some features of cri-du-chat syndrome. Hum Genet 97: 802–807.

      46. Malan V, Martinovic J, Sanlaville D, Caillat S, Waill M-CP, Ganne M-LM, et al. (2006): Molecular characterisation of a prenatally diagnosed 5q15q21.3 deletion and review of the literature. Prenat Diagn 26: 231–238.

      47. Brown KK, Alkuraya FS, Matos M, Robertson RL, Kimonis VE, Morton CC (2009): NR2F1 deletion in a patient with a de novo paracentric inversion, inv(5)(q15q33.2), and syndromic deafness. Am J Med Genet A 149A: 931–938.

      48. Al-Kateb H, Shimony JS, Vineyard M, Manwaring L, Kulkarni S, Shinawi M (2013): NR2F1 haploinsufficiency is associated with optic atrophy, dysmorphism and global developmental delay. Am J Med Genet A 161A: 377–381.

      49. Smith CL, Bolton A, Nguyen G (2010): Genomic and epigenomic instability, fragile sites, schizophrenia and autism. Curr Genomics 11: 447–469.

      50. Ang CE, Ma Q, Wapinski OL, Fan S, Flynn RA, Lee QY, et al. (2019): The novel lncRNA lnc-NR2F1 is pro-neurogenic and mutated in human neurodevelopmental disorders. Elife 8. https://doi.org/10.7554/eLife.41770

      51. Bertacchi M, Gruart A, Kaimakis P, Allet C, Serra L, Giacobini P, et al. (2019): Mouse Nr2f1 haploinsufficiency unveils new pathological mechanisms of a human optic atrophy syndrome. EMBO Mol Med 11: e10291.

      52. Zhang K, Yu F, Zhu J, Han S, Chen J, Wu X, et al. (2020): Imbalance of Excitatory/Inhibitory Neuron Differentiation in Neurodevelopmental Disorders with an NR2F1 Point Mutation. Cell Rep 31: 107521.

      53. Del Pino I, Tocco C, Magrinelli E, Marcantoni A, Ferraguto C, Tomagra G, et al. (2020): COUP-TFI/Nr2f1 Orchestrates Intrinsic Neuronal Activity during Development of the Somatosensory Cortex. Cereb Cortex 30: 5667–5685.

      54. Manikandan M, Abuelreich S, Elsafadi M, Alsalman H, Almalak H, Siyal A, et al. (2018): NR2F1 mediated down-regulation of osteoblast differentiation was rescued by bone morphogenetic protein-2 (BMP-2) in human MSC. Differentiation 104: 36–41.

      55. Rech ME, McCarthy JM, Chen C, Edmond JC, Shah VS, Bosch DGM, et al. (2020): Phenotypic expansion ofBosch–Boonstra–Schaafoptic atrophy syndrome and further evidence for genotype–phenotype correlations. American Journal of Medical Genetics Part A, vol. 182. pp 1426–1437.

      56. Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, et al. (2012): Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer. PLoS One 7: e46467.

      57. Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, et al. (2015): NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nature Communications, vol. 6. https://doi.org/10.1038/ncomms7170

      58. Tang K, Tsai SY, Tsai M-J (2015): COUP-TFs and eye development. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol. 1849. pp 201–209.

      59. Shibata H, Ando T, Suzuki T, Kurihara I, Hayashi K, Hayashi M, et al. (1998): COUP-TFI Expression in Human Adrenocortical Adenomas: Possible Role in Steroidogenesis. The Journal of Clinical Endocrinology & Metabolism, vol. 83. pp 4520–4520.

      60. Jain P, Miller-Fleming T, Topaloudi A, Yu D, Drineas P, Georgitsi M, et al. (2022, September 2): Polygenic risk score-based phenome-wide association study identifies novel associations for Tourette syndrome. bioRxiv. https://doi.org/10.1101/2022.09.01.22279340